Pfizer has made a new and improved bid to acquire AstraZeneca with an offer worth £69.3 billion pounds ($116.6 billion) or £55 a share – and says this is its best and final offer for the firm.

Pfizer and AstraZeneca Debate: When “the Greater Good” Matters The business pages, and now the mainstream media, have been dominated over the last week with news of Pfizer’s proposed $106bn ...

AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...

As of November 25, Pfizer's forward P/E ratio is just 8.8, considerably lower than Eli Lilly at 56.5 and AstraZeneca at 16.2. Pfizer also has a competitive price-to-book ratio of 1.54.

The deal gives AstraZeneca’s rare disease unit Alexion access to specialized capsids developed by the Japanese biotech JCR ...

AstraZeneca (NASDAQ: AZN) and Pfizer (NYSE: PFE) -- along with one biotech stock, Exelixis (NASDAQ: EXEL). (AstraZeneca): ...

After several PD-1xVEGF competitors forged alliances with Big Pharma players, Summit Therapeutics, the frontrunner in this hot cancer drug field, is reportedly seeking its own deal. | After several PD ...

Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on ...

Bernstein analyst Justin Smith maintained a Hold rating on Pfizer yesterday and set a price target of $30.00. The company’s shares closed yesterday at $25.62. Don’t Miss TipRa ...

As of November 25, Pfizer's forward P/E ratio is just 8.8, considerably lower than Eli Lilly at 56.5 and AstraZeneca at 16.2. Pfizer also has a competitive price-to-book ratio of 1.54.